SPR Oncocare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: SPR Oncocare Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $78.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SPR Oncocare Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $78.5K Trade | TransData Nexus

SPR Oncocare Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $78.5K Total Trade · DGFT Verified

SPR Oncocare Private Limited is an Indian pharmaceutical exporter with a total trade value of $78.5K across 3 products in 1 therapeutic categories. Based on 11 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cetuximab ($37.8K), Pembrolizumab ($26.8K), Olaparib ($13.9K).

SPR Oncocare Private Limited — Export Portfolio & Destination Treemap

SPR Oncocare Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is SPR Oncocare Private Limited? — Company Overview & Market Position

SPR Oncocare Private Limited is a private company incorporated on July 22, 2011, under the Corporate Identification Number (CIN) U51909KA2011PTC059691. The company is registered with the Registrar of Companies in Bangalore, Karnataka, India. Its authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. The registered office is located at No 12/1, 100 Feet Varthula Road, Anjaneya Nagar, Kathriguppe, Bangalore, Karnataka, 560085.

SPR Oncocare specializes in the wholesale trade of pharmaceutical products, focusing on anti-cancer formulations and herbal extracts. The company's product portfolio includes items such as Gefitinib Tablets, Lenvatinib Capsules, Vandetanib Tablets, and various herbal extracts like Ashwagandha and Curcumin.

What Does SPR Oncocare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cetuximab$37.8K 2Pembrolizumab$26.8K

Product Portfolio — Top 3 by Export Value

SPR Oncocare Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cetuximab	Advanced Oncology	$37.8K	4	4.5%	4
2	Pembrolizumab	Advanced Oncology	$26.8K	3	1.4%	12
3	Olaparib	Advanced Oncology	$13.9K	4	1.5%	8

SPR Oncocare Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $78.5K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

SPR Oncocare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding SPR Oncocare's manufacturing facilities are not publicly disclosed. The company is primarily engaged in trading, distributing, and outsourcing pharmaceutical products, with a specialization in new molecules and anti-cancer formulations.

3Key Leadership

The company's board of directors includes:

Rajashri Prasad
Kaliyur Nagappa Shiva Prasad
Mangalagowri Nag
Prakruthi Prasad

The role of Chief Executive Officer (CEO) or Managing Director (MD) is not explicitly mentioned in the available sources. The company's email contact is [email protected].

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does SPR Oncocare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SPR Oncocare's export activities are primarily focused on the advanced oncology therapeutic category, with a total export value of $78,000 USD across 11 shipments. The top three exported products are:

Cetuximab: $38,000 USD (Rank #4, 4.5% market share)
Pembrolizumab: $27,000 USD (Rank #12, 1.4% market share)
Olaparib: $14,000 USD (Rank #8, 1.5% market share)

These figures indicate a concentrated portfolio, with the top three products accounting for 100% of the company's export value.

2Emerging Markets

SPR Oncocare has expressed interest in exporting to various countries, including Anguilla, Austria, Barbados, Belgium, Canada, China, Hong Kong S.A.R., Hungary, United Kingdom, and the United States. This suggests a strategic focus on both developed and emerging markets. (sproncocareprivateli.linker.store)

Geographic Strategy

SPR Oncocare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding SPR Oncocare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on trading and outsourcing suggests that it may not have direct FDA approvals for its products.

2WHO & EU GMP

Specific details about SPR Oncocare's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available.

3CDSCO & Indian Regulatory

Information regarding SPR Oncocare's compliance with the Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) is not publicly disclosed.

Recent Regulatory Actions

SPR Oncocare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

SPR Oncocare operates in a competitive market, with competitors including AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. The company's focus on anti-cancer formulations and herbal extracts positions it in a niche segment, potentially reducing direct competition.

2Key Differentiators

SPR Oncocare's specialization in new molecules and anti-cancer formulations, along with its engagement in contract manufacturing and trading, distinguishes it from competitors. The company's interest in exporting to a diverse set of countries indicates a proactive approach to market expansion.

3Strategic Position

SPR Oncocare's current strategic direction appears to be focused on trading, distributing, and outsourcing pharmaceutical products, with an emphasis on anti-cancer formulations and herbal extracts. The company's future outlook may involve expanding its product portfolio and enhancing its presence in both developed and emerging markets.

Buyer Due Diligence Brief — Evaluating SPR Oncocare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SPR Oncocare's track record in exporting pharmaceutical products, particularly in the oncology segment, indicates a level of reliability. However, the concentration of its export value in a few products suggests potential risks associated with market fluctuations affecting these specific drugs.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website.

WHO-GMP: Ensure that the manufacturing facilities comply with World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website.

EU GMP: Check for compliance with European Union Good Manufacturing Practices. Verification can be done through the European Medicines Agency's official website.

Frequently Asked Questions — SPR Oncocare Private Limited

How many pharmaceutical products does SPR Oncocare Private Limited export from India?

SPR Oncocare Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Cetuximab ($37.8K), Pembrolizumab ($26.8K), Olaparib ($13.9K). Total export value is $78.5K.

What is SPR Oncocare Private Limited's total pharmaceutical export value?

SPR Oncocare Private Limited's total pharmaceutical export value is $78.5K, based on 11 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does SPR Oncocare Private Limited cover?

SPR Oncocare Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 3 products).

Get Full SPR Oncocare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.